cetylpyridinium chloride anhydrous has been researched along with Pituitary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Ramírez, LC; Stratakis, CA; Trivellin, G | 1 |
| Biermasz, NR; Dekkers, OM; Pereira, AM; Rabe, KF; Romijn, JA; Smit, JW; van der Klaauw, AA; van Kralingen, KW | 1 |
1 review(s) available for cetylpyridinium chloride anhydrous and Pituitary Neoplasms
| Article | Year |
|---|---|
Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease.
Topics: Animals; Cyclic AMP; Disease; Health; Humans; Pituitary Gland, Anterior; Pituitary Neoplasms; Signal Transduction | 2018 |
1 other study(ies) available for cetylpyridinium chloride anhydrous and Pituitary Neoplasms
| Article | Year |
|---|---|
Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Craniopharyngioma; Disorders of Excessive Somnolence; Female; Health; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Research Design; Sleep; Surveys and Questionnaires | 2008 |